2025
Pregnancy Length Measurement Error: A comparison of Last Menstrual Period and Ultrasonography with Ovulation-Based Estimation.
Doss G, Daniels J, Mumford S, Poole C, Steiner A, Schisterman E, Silver R, Klawans M, Jukic A. Pregnancy Length Measurement Error: A comparison of Last Menstrual Period and Ultrasonography with Ovulation-Based Estimation. Epidemiology 2025 PMID: 40981999, DOI: 10.1097/ede.0000000000001918.Peer-Reviewed Original ResearchPreterm birthGestational ageMenstrual periodCrown-rump length measurementsLast menstrual periodPregnancy lengthSingleton live birthsUS medical centersEffect of aspirinLive birthsPretermPregnancyGold standardMedical CenterFertility monitorBirthGestationUltrasoundLMPOvulationAgeLength measurementsUltrasonographyAnalytic sampleAspirin
2022
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPreventionImplementation of an Electronic Health Record Integrated Clinical Pathway Improves Adherence to COVID-19 Hospital Care Guidelines
Sangal RB, Liu RB, Cole KO, Rothenberg C, Ulrich A, Rhodes D, Venkatesh AK. Implementation of an Electronic Health Record Integrated Clinical Pathway Improves Adherence to COVID-19 Hospital Care Guidelines. American Journal Of Medical Quality 2022, 37: 335-341. PMID: 35026785, PMCID: PMC9241559, DOI: 10.1097/jmq.0000000000000036.Peer-Reviewed Original ResearchConceptsClinical pathwaySecondary outcomesCOVID-19 treatment guidelinesEmergency department cliniciansIntegrated clinical pathwayCOVID-19Electronic health recordsPrimary outcomeTreatment guidelinesClinician adherenceED cliniciansED patientsCare guidelinesTreatment recommendationsMedication administrationPatient outcomesPatient carePatientsCliniciansHealth systemHealth recordsOutcomesAdherenceAspirinCOVID-19 pandemic
2021
Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗
Bittl JA, Laine L. Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗. Journal Of The American College Of Cardiology 2021, 79: 129-131. PMID: 34752903, DOI: 10.1016/j.jacc.2021.10.027.Commentaries, Editorials and LettersComparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation
Vavuranakis M, Kalantzis C, Voudris V, Kosmas E, Kalogeras K, Katsianos E, Oikonomou E, Siasos G, Aznaouridis K, Toutouzas K, Stasinopoulou M, Tountopoulou A, Bei E, Moldovan C, Vrachatis D, Iakovou I, Papaioannou T, Tousoulis D, Leucker T, Vavuranakis M. Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2021, 154: 78-85. PMID: 34243938, DOI: 10.1016/j.amjcard.2021.05.047.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationHigh-intensity transient signalsP2Y12 reaction unitsPlatelet inhibitionAortic valve implantationMicroembolic eventsValve implantationTranscranial DopplerExtra-cardiac arteriopathyEffects of ticagrelorVARC-2 definitionsClopidogrel groupTicagrelor groupBalloon valvuloplastyVARC-2Antiplatelet regimenTicagrelorClopidogrelPatientsSafety outcomesReaction unitsPlateletTranscatheterAspirinInhibition
2020
Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)
Ong SY, Chui P, Bhargava A, Justice A, Hauser RG. Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System). The American Journal Of Cardiology 2020, 137: 25-30. PMID: 32991852, DOI: 10.1016/j.amjcard.2020.09.042.Peer-Reviewed Original ResearchConceptsLow-dose aspirinElectronic health recordsSelf-reported useEHR dataPatients' self-reported useLow-dose aspirin useAtherosclerotic cardiovascular diseaseAmerican Heart AssociationEHR recordsNon-specific terminologyAspirin usePrimary preventionHeart AssociationCardiovascular diseaseAmerican CollegeAspirinPatientsHealth recordsEHR implementationEHR searchesImplementable guidelinesGuidelinesRecordsDiseaseCardiologyCan Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents?
Merriam A, Paidas M. Can Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents? 2020, 223-230. DOI: 10.1201/9780429450303-24.ChaptersRecurrent pregnancy lossPregnancy outcomesAntiplatelet agentsPregnancy lossAntithrombotic agentsMultiple adverse pregnancy outcomesSmall case-control studyAntiplatelet agent aspirinAdverse pregnancy outcomesSuccessful pregnancy outcomeCase-control studyMultiple prospective studiesHistory of thrombophiliaClass of drugsEffects of anticoagulantsAspirin treatmentProspective studyAnticoagulant agentsLive birthsThrombophiliaBlood clotsWomenAspirinOutcomesAgents
2019
Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
Copel JA, Platt LD, Hobbins JC, Afshar Y, Grechukhina O, Mallampati D, Bromley B, Caughey AB, Grobman W, Han CS, Nicolaides K, Pettker C, Saade G, Sibai B, Simhan H, Sonek J, Werner E, Chescheir N. Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Obstetrics And Gynecology 2019, 135: 36-45. PMID: 31809427, DOI: 10.1097/aog.0000000000003582.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEarly-onset preeclampsiaSubstantial economic burdenCost-effectiveness dataAspirin prophylaxisNeonatal morbidityPreterm preeclampsiaProphylactic usePreventive strategiesEconomic burdenPreeclampsiaCurrent professional guidelinesRisk assessment strategiesRisk assessmentPractice changeDifferent assessment toolsSpecific knowledge gapsAspirinUnited StatesTarget populationConsequent interventionsFeasibility of implementationProfessional guidelinesAssessment toolAvailable literatureRiskInduction of Secretagogue Independent Gastric Acid Secretion via a Novel Aspirin-Activated Pathway
Kitay AM, Ferstl FS, Link A, Geibel JP. Induction of Secretagogue Independent Gastric Acid Secretion via a Novel Aspirin-Activated Pathway. Frontiers In Physiology 2019, 10: 1264. PMID: 31649553, PMCID: PMC6795678, DOI: 10.3389/fphys.2019.01264.Peer-Reviewed Original ResearchGastric acid secretionNon-selective NOS inhibitor L-NAMENOS inhibitor L-NAMEInhibitor L-NAMEAcid secretionL-NAMESoluble guanylyl cyclase inhibitor 1HGuanylyl cyclase inhibitor 1HIncreases nitric oxide productionUsage of aspirinGastric glandsPH-sensitive dye BCECF-AMNitric oxide productionVariety of cancersNovel secretagogueBlood clot formationAspirin exposureChronic conditionsMucosal barrierRepetitive dosesUlcer formationAspirin consumptionBasolateral exposureAspirinClot formationHospitalization among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated with Apixaban or Aspirin: Insights from the AUGUSTUS Trial
Vora A, Alexander J, Wojdyla D, Aronson R, Granger C, Darius H, Windecker S, Mehran R, Averkov O, Budaj A, Kong D, Kobalava Z, Mehta R, Mirza Z, Guimaraes P, Parkhomenko A, Quadros A, Thiele H, Goodman S, Lopes R. Hospitalization among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated with Apixaban or Aspirin: Insights from the AUGUSTUS Trial. Circulation 2019, 140: 1960-1963. PMID: 31553201, DOI: 10.1161/circulationaha.119.043754.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAspirinAtrial FibrillationCardiovascular AgentsCombined Modality TherapyDrug Therapy, CombinationElective Surgical ProceduresFemaleFibrinolytic AgentsHemorrhageHospitalizationHumansLength of StayMaleMiddle AgedMulticenter Studies as TopicPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesPurinergic P2Y Receptor AntagonistsPyrazolesPyridonesRandomized Controlled Trials as TopicSurvival AnalysisTreatment OutcomeVitamin KConceptsNon-vitamin K oral anticoagulantsAcute coronary syndromePercutaneous coronary interventionVitamin K antagonistsAtrial fibrillationOral anticoagulantsCoronary syndromePatients treated with aspirinOptimal antithrombotic therapyIncreased bleeding riskRate of bleedingComposite of deathAUGUSTUS trialRate of deathK antagonistsCombination therapyAntithrombotic therapyBleeding riskP2Y12 inhibitorsSecondary outcomesCoronary interventionRandomized treatmentAspirinPatientsApixaban
2018
ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer.
Chen W, Winer E, Barry W, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer. Journal Of Clinical Oncology 2018, 36: tps597-tps597. DOI: 10.1200/jco.2018.36.15_suppl.tps597.Peer-Reviewed Original Research
2017
Aspirin for Primary Prevention
Richman IB, Owens DK. Aspirin for Primary Prevention. 2017, 101: 713-724. PMID: 28577622, DOI: 10.1016/j.mcna.2017.03.004.BooksMeSH KeywordsAge FactorsAspirinCardiovascular DiseasesColorectal NeoplasmsDiabetes MellitusGastrointestinal HemorrhageHumansHypertensionLipidsMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicPrimary PreventionRacial GroupsRisk AssessmentRisk FactorsSex FactorsSmokingStrokeConceptsColorectal cancerPrimary preventionCardiovascular diseaseUS Preventive Services Task ForceNonfatal myocardial infarctionCardiovascular disease riskAdults age 50Intracranial bleedingOlder patientsMyocardial infarctionSelect populationAge 50AspirinAdults 60Disease riskAvailable evidenceRiskCancerDiseasePreventionTask ForceBleedingInfarctionPatientsStrokeABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.
Chen W, Winer E, Barry W, Hudis C, Openshaw T, Visvanathan K, Symington B, Matyka C, Holmes M. ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. Journal Of Clinical Oncology 2017, 35: tps586-tps586. DOI: 10.1200/jco.2017.35.15_suppl.tps586.Peer-Reviewed Original ResearchAspirin usersRegular aspirin usersBreast cancer survivalMultiple epidemiologic studiesAnti-tumor activityMetastatic adenocarcinomaRandomized trialsDecreased riskCancer survivalCardiovascular diseaseMetastatic cancerEpidemiologic studiesAvailable drugsVivo evidenceAspirinMultiple pathwaysAdenocarcinomaCancerDiseaseTrialsAspirin Use and Reduced Risk of Pancreatic Cancer
Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 68-74. PMID: 27999143, PMCID: PMC5225096, DOI: 10.1158/1055-9965.epi-16-0508.Peer-Reviewed Original ResearchConceptsPancreatic cancerAspirin useRegular useConfidence intervalsLong-term aspirin useControl subjects frequencyLow-dose aspirinAvoidance of smokingBody mass indexPopulation-based studyUnconditional logistic regressionABO blood groupRisk-benefit analysisAspirin typeCagA seropositivityDiabetes mellitusMass indexCigarette smokingCardiovascular diseaseAspirinCancerCertain cancersLogistic regressionBlood groupSubjects frequency
2016
090 Aspirin Does Not Have a Significant Impact on Loop Diuretic Response or Renin Release in Heart Failure Patients
Broughton J, Hanberg J, Assefa M, Rao V, Testani J. 090 Aspirin Does Not Have a Significant Impact on Loop Diuretic Response or Renin Release in Heart Failure Patients. Journal Of Cardiac Failure 2016, 22: s34-s35. DOI: 10.1016/j.cardfail.2016.06.108.Peer-Reviewed Original ResearchComparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites
Gamboa JL, Devin JK, Ramirez CE, Yu C, Nian H, Lee RH, Brown NJ. Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites. Pharmacology Research & Perspectives 2016, 4: e00221. PMID: 27069632, PMCID: PMC4804312, DOI: 10.1002/prp2.221.Peer-Reviewed Original ResearchProstacyclin metaboliteThromboxane productionProstacyclin productionBasal excretionDoses of ASAImmediate-release aspirinStable prostacyclin metaboliteBasal urinary excretionInhibition of basalAspirin therapyIntravenous bradykininASA groupThromboxane metabolitesUrinary excretionEndothelial productionTreatment periodHealthy subjectsCrossover designThromboxane formationAspirinPlatelet aggregationExcretionProstacyclinThromboxaneFifth day
2014
Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study
Gao Y, Masoudi FA, Hu S, Li J, Zhang H, Li X, Desai NR, Krumholz HM, Jiang L, Group T. Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study. Journal Of The American Heart Association 2014, 3: e001250. PMID: 25304853, PMCID: PMC4323779, DOI: 10.1161/jaha.114.001250.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAspirinChinaCohort StudiesConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionOdds RatioRetrospective StudiesRisk AssessmentRural PopulationSecondary PreventionSex FactorsSurvival AnalysisSurvival RateUrban PopulationConceptsAcute myocardial infarctionMyocardial infarctionAspirin useEarly treatmentSegment elevation acute myocardial infarctionElevation acute myocardial infarctionEarly useChina PEACE-Retrospective AMI StudyEarly aspirin therapyEarly aspirin useLimited healthcare resourcesAspirin therapyCardiogenic shockChest discomfortReperfusion therapyRate of useChina PatientRetrospective studyPatient groupFinal diagnosisHealthcare resourcesInfarctionPatientsAspirinAMI studyCase–Control Study of Aspirin Use and Risk of Pancreatic Cancer
Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case–Control Study of Aspirin Use and Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 1254-1263. PMID: 24969230, PMCID: PMC4091763, DOI: 10.1158/1055-9965.epi-13-1284.Peer-Reviewed Original ResearchConceptsAspirin usePancreatic cancerLong-term aspirin useLow-dose aspirinCase-control studyCalendar time periodTime of interviewRisk-benefit analysisAspirin regimenCardiovascular diseaseReduced riskYear of interviewPossible associationCancerConnecticut StudyRegular useAspirinRiskCase frequencySignificant relationshipYearsRegimenComplicationsPrognosisMortality
2013
Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin
Moeckel GW, Luciano RL, Brewster UC. Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin. Clinical Kidney Journal 2013, 6: 507-509. PMID: 26120444, PMCID: PMC4438392, DOI: 10.1093/ckj/sft076.Peer-Reviewed Case Reports and Technical NotesAcute kidney injuryTubular injuryIgA nephropathyMild IgA nephropathyAcute tubular injuryLong-term anticoagulationDirect thrombin inhibitorKidney injurySevere hematuriaRenal biopsyGlomerular pathologyDabigatranPatientsThrombin inhibitorsNephropathyInjuryWarfarinAnticoagulationHematuriaAspirinBiopsyPathology
2012
IMPACT OF HIGH DOSE ASPIRIN IN MEN VS. WOMEN AFTER ACUTE MYOCARDIAL INFARCTION: RESULTS FROM THE HORIZONS-AMI TRIAL
Yu J, Mehran R, Vlachojannis G, Baber U, Xu K, Lansky A, Grines C, Guagliumi G, Kornowski R, Witzenbichler B, Dangas G, Stone G. IMPACT OF HIGH DOSE ASPIRIN IN MEN VS. WOMEN AFTER ACUTE MYOCARDIAL INFARCTION: RESULTS FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2012, 59: e272. DOI: 10.1016/s0735-1097(12)60273-3.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply